Back to top

Image: Bigstock

Factors Likely to Decide Deckers' (DECK) Fate in Q1 Earnings

Read MoreHide Full Article

Deckers Outdoor Corporation (DECK - Free Report) is slated to report first-quarter fiscal 2020 results on Jul 25, after the closing bell. In the last four quarters, this Goleta, CA-based footwear and apparel retailer’s bottom-line has outperformed the Zacks Consensus Estimate by a wide margin. Investors are counting on another beat by Deckers in the to-be-reported quarter. If all goes well, this will be the 10th straight quarter of positive earnings and sales surprise.

The Zacks Consensus Estimate for the quarter under review is pegged at a loss of $1.15. The company had reported loss of 98 cents in the year-ago quarter. We note that the Zacks Consensus Estimate has remained unchanged in the past 30 days. The consensus estimate for revenues stands at $259.9 million, suggesting an increase of approximately 3.7% from the year-ago quarter.

For first-quarter fiscal 2020, Deckers had earlier guided net sales in the range of $250-$260 million with bottom-line loss of $1.15-$1.25 per share.

Key Factors Influencing Q1

Deckers has been targeting profitable markets, and is focused on product innovation and store-augmentation plan. Further, the company’s commitment toward expanding brand assortments, bringing more innovative line of products, targeting consumers through marketing and optimizing omni-channel distribution bodes well. In keeping with the changing trends, Deckers has made substantial investments to strengthen online presence and open smaller concept omni-channel outlets. These are likely to have a favorable impact on the first-quarter’s performance.

However, industry experts are concerned about Deckers' over-reliance on the UGG brand. In the event of stagnation or decline in UGG sales growth, the company's overall results will be affected. This is because the percentage of contribution from the company’s other brands are minimal to offset any slowdown in UGG sales. We also note that the company has been grappling with falling sales from the Sanuk Brand. Moreover, headwinds related to currency, freight expense and higher promotional environment cannot be ignored. This might weigh on margins to an extent and in turn the bottom line.

The Zacks Consensus Estimate for sales for UGG brand stands at $135 million for the quarter under review, indicating a decline of roughly 1.5% year over year. The consensus estimates for sales for Sanuk and Teva brands are pegged at $24.40 million and $40 million, flat year over year.

Deckers Outdoor Corporation Price, Consensus and EPS Surprise
 

Deckers Outdoor Corporation Price, Consensus and EPS Surprise

Deckers Outdoor Corporation price-consensus-eps-surprise-chart | Deckers Outdoor Corporation Quote

What the Zacks Model Unveils

Our proven model does not conclusively show that Deckers is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Deckers has a Zacks Rank #2 and an Earnings ESP of 0.00%, consequently making the surprise prediction difficult.

3 Stocks With a Favorable Combination

Here are three companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat:

L Brands (LB - Free Report) has an Earnings ESP of +0.89% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Carter's, Inc. (CRI - Free Report) has an Earnings ESP of +0.50% and a Zacks Rank #3.

Columbia Sportswear Company (COLM - Free Report) has an Earnings ESP of +40.00% and a Zacks Rank #3.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119%and +164%in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>